June 6, 2013 PLANDAI BENEFITS FROM INDUSTRY’S EGCG ALZHEIMER STUDIES According to a recent study published in the Journal of Biology Chemistry, Epigallocatechin gallate (EGCG), the most abundant catechin found in green tea, has demonstrated the ability to serve as a treatment for Alzheimer’s disease. Success in developing a treatment for or prevention of Alzheimer’s could have a very favorable impact on Plandai Biotechnology Inc. (OTCQB – PLPL - $0.53 – Spec Buy), which develops highly bioavailable, phytonutrient rich extracts (like EGCG) utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. In fact, Plandaí's Phytofare™ Catechin Complex is processed to deliver a highly bioavailable, antioxidant- rich material containing EGCG and the other gallate catechins in green tea at a level many times that of other extracts available on the market. The Alzheimer study, which occurred in the lab, was shown to stop amyloid-beta proteins from attaching to and killing brain cells in a lab setting by changing the shape of the proteins by applying ECGC. These proteins have been identified in many studies and trials as proteins that play a role in the disease. The Alzheimer’s Association notes that Alzheimer's disease is the sixth-leading cause of death in the United States and the only cause of death among the top 10 in the United States that cannot be prevented, cured or even slowed. As a result, according to the National Institutes of Health, over 1,000 clinical trials are underway to fight this disease, which affects 5 million people in the U.S and is expected to nearly triple by 2050. Clearly, additional studies will be undertaken to eventually confirm these early results in a human clinical trial setting. Given that Plandai’s Phytofare™ is engineered to produce extremely high bioavailability and pharmaceutical-grade purity, the Company could emerge as a primary source of ECGC via its Phytofare™ Catechin Complex for these studies. Moreover, these encouraging results could prompt greater consumption of green tea and its antioxidant extracts as an Alzheimer’s preventive tool. Therefore, producers touting ECGC’s properties in such treatments could select Plandai as a large scale, go-to source of extract in its offerings, serving as a boon to Plandai’s business and industry status. For more information, refer to our previous PLPL Reports, Updates and Hot Topics by visiting www.GoldmanResearch.com Senior Analyst: Robert Goldman Analyst Certification Disclaimer The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority. ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION. |